USPTO Examiner ROBINSON HOPE A - Art Unit 1652

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18662443REGENERATIVE POLYPEPTIDES AND USES THEREOFMay 2024February 2025Allow920YesNo
18596638PROTEOMICS REACTOR, PROTEIN CHROMATOGRAPHIC SEPARATION PLATFORM AND USE THEREOFMarch 2024September 2024Allow610YesNo
18409699TRANSAMINASE POLYPEPTIDESJanuary 2024June 2025Allow1811YesNo
18404047CHITIN AND PROCESS FOR PRODUCING CHITIN AND/OR CHITOSAN BY THE ENZYMATIC AND CHEMICAL PATHWAYJanuary 2024February 2025Allow1310YesNo
18389919ANTICOAGULANT FUSION PROTEINS AND USES THEREOFDecember 2023January 2025Abandon1301NoNo
18528794METHOD OF ETHANOL FERMENTATION WITH CELLULOSE AT HIGH-SOLIDS LOADINGDecember 2023April 2025Allow1640YesNo
18339995SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOFJune 2023January 2025Abandon1901NoNo
18167707PROCESS OF EXTRACTING OIL FROM THIN STILLAGEFebruary 2023May 2025Allow2720YesNo
18060517TRANSAMINASE POLYPEPTIDESNovember 2022September 2023Allow1011YesNo
18059949BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDSNovember 2022November 2024Allow2311YesNo
17937111SELECTIVE SELF-ASSEMBLY BASED ARTIFICIAL METABOLON, PRODUCTION AND USE THEREOFSeptember 2022April 2025Abandon3121NoNo
17931687ENGINEERED TYROSINE AMMONIA LYASESeptember 2022August 2023Abandon1110NoNo
17931677ENGINEERED TYROSINE AMMONIA LYASESeptember 2022August 2023Abandon1101NoNo
17899069Production of Steviol Glycosides in Recombinant HostsAugust 2022July 2024Allow2211NoNo
17821297VARIANTS AND COMPOSITIONS COMPRISING VARIANTS WITH HIGH STABILITY IN PRESENCE OF A CHELATING AGENTAugust 2022December 2023Allow1611NoNo
17891385CANNABINOID AND TERPENE PRESERVATION IN BIOMASS USING WHOLE FERMENTATION BROTHAugust 2022March 2024Allow1921YesNo
17817783ENGINEERED TYROSINE AMMONIA LYASEAugust 2022June 2023Abandon1001NoNo
17817261Factor VIII SequencesAugust 2022October 2024Abandon2620YesNo
17772825STRAIN WITH IMPROVED AROMATIC AMINO ACID PRODUCTION CAPACITY BY GLSB GENE INACTIVATIONApril 2022June 2025Abandon3810NoNo
17703519METHOD FOR PRODUCING 2-METHYL-BUTYRIC ACID BY BACTERIAL FERMENTATIONMarch 2022April 2025Allow3710YesNo
17698576ENGINEERED HEME-BINDING COMPOSITIONS AND USES THEREOFMarch 2022November 2023Allow2011NoNo
17694779Acid Phosphatase Mutants and Methods of Using the SameMarch 2022April 2025Allow3721YesNo
17687786METHOD OF GLYCATION OF A POLYPEPTIDEMarch 2022September 2023Allow1811YesNo
17636351BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORSFebruary 2022March 2025Abandon3710NoNo
17631985TUNING PROTEIN SOLUBILITY BY POLYMER SURFACE MODIFICATIONFebruary 2022February 2025Abandon3701NoNo
17583026MANUFACTURING OF GLYCOPROTEINSJanuary 2022November 2022Abandon1000NoNo
17574406PRODUCTION OF CATALYTICALLY ACTIVE TYPE I SULFATASEJanuary 2022February 2024Abandon2501NoNo
17625782ESTERASES AND METHODS OF USING THE SAMEJanuary 2022March 2025Allow3811YesNo
17569374Method of Inhibiting C5 CleavageJanuary 2022December 2024Abandon3521YesNo
17622619COMPOSITIONS AND METHODS FOR SYNTHESIS OF TERPENOIDSDecember 2021January 2025Abandon3701NoNo
17559782METHOD OF PURIFYING AND ISOLATING COLLAGENASEDecember 2021June 2025Allow4241NoNo
17619360METHOD FOR THE PRODUCTION OF ETHANOL FROM CORN FIBERSDecember 2021January 2025Allow3710YesNo
17550300ANIMAL FEED WITH ENGINEERED PHYTASESDecember 2021August 2023Allow2021YesNo
17548196STABILIZED THROMBINDecember 2021September 2024Allow3350YesNo
17534399CELL CULTURE MEDIUMNovember 2021July 2025Allow4351YesNo
17610741SYNERGISTIC COMBINATIONS OF ARGININE-PRODUCING BACTERIA AND/OR AMMONIA-CONSUMING BACTERIA AND CHECKPOINT INHIBITORS AND METHODS OF USE THEREOFNovember 2021November 2024Abandon3601NoNo
17524466COMPOSITIONS COMPRISING NUCLEIC ACID MOLECULES AND METHODS OF TREATING ATPASE-MEDIATED DISEASESNovember 2021March 2023Allow1621YesNo
17519545CELL-TARGETED CYTOTOXIC CONSTRUCTSNovember 2021November 2023Allow2410YesNo
17509504Processes for Producing EthanolOctober 2021June 2023Allow2011YesNo
17499599A METHOD FOR PRODUCING DIHYDROTENTOXINOctober 2021September 2023Allow2311YesNo
17601673PRODUCTION OF CANNABINOIDSOctober 2021January 2025Abandon3921NoNo
17599153ENZYME NANOPARTICLES WITH METHANE OXIDATION ACTIVITYSeptember 2021November 2024Allow3821YesNo
17470811POLYMER-FACTOR VIII MOIETY CONJUGATESSeptember 2021June 2024Abandon3421NoNo
17458075COVALENT MODIFICATION OF BIOLOGICAL MACROMOLECULESAugust 2021April 2023Abandon2001NoNo
17411590ENZYME EXTRACTION METHODSAugust 2021April 2025Allow4441YesNo
17410262METHODS FOR PRODUCING ETHANOLAugust 2021June 2023Allow2110YesNo
17428344POLYNUCLEOTIDESAugust 2021September 2024Allow3741YesNo
17425288GENETICALLY ENGINEERED YEAST YARROWIA LIPOLYTICA AND METHODS FOR PRODUCING BIO-BASED GLYCOLIC ACIDJuly 2021February 2025Abandon4311NoNo
17380714Method for Producing y-aminobutyric Acid (GABA) by Fermentation of Native Strain from Raw Material of Sayram KettekiJuly 2021February 2025Abandon4331YesNo
17262184A METHOD OF TREATING PATHOGENIC BACTERIAL INFECTIOUS DISEASESJuly 2021December 2024Allow4720YesNo
17369830Compositions for Treating Pathological Calcification Conditions, and Methods Using SameJuly 2021June 2024Allow3511YesNo
17367212ENGINEERED PICHIA STRAIN AND A RECOMBINANT METHOD OF USING THE SAME FOR MAKING A COLLAGEN SPONGEJuly 2021January 2025Allow4220YesNo
17355962CMP-DEPENDENT SIALIDASE ACTIVITYJune 2021June 2023Allow2310YesNo
17354628Method for Producing Basic L-Amino Acids or Salts Thereof By Fermentation of an Enterobacteriaceae BacteriumJune 2021January 2024Allow3120YesNo
17312763BIOLOGICALS AND THEIR USE IN PLANTSJune 2021January 2025Abandon4301NoNo
17340271Polypeptides having Alpha-Galactosidase Activity and Polynucleotides Encoding SameJune 2021May 2023Allow2311YesNo
17338508Method of treating AML with PEGylated L-AsparaginaseJune 2021June 2025Allow4850YesNo
17299647BILIRUBIN OXIDASE ACTIVITY IMPROVING METHOD, AND BILIRUBIN OXIDASE PRODUCTJune 2021October 2024Abandon4121NoNo
17293794RECOMBINANT VECTOR, HOST CELL AND PROCESS FOR PRODUCTION OF HUMAN SERUM ALBUMINMay 2021April 2025Abandon4820NoNo
17291821BIOCATALYTIC METHOD FOR PRODUCING 2H-HBO AND �-SUBSTITUTED ANALOGUES FROM LGO USING A CYCLOHEXANONE MONOOXYGENASEMay 2021December 2024Abandon4331YesNo
17306386METHODS AND SYSTEMS FOR THE DETECTION AND REMOVAL OF PATHOGENS FROM BLOODMay 2021June 2024Abandon3741YesNo
17242181ENGINEERED TYROSINE AMMONIA LYASEApril 2021September 2022Abandon1711YesNo
17288676Method of Precipitating PhytaseApril 2021March 2023Abandon2311NoNo
17240715POLYPEPTIDE TAG, HIGHLY SOLUBLE RECOMBINANT NITRILASE AND APPLICATION THEREOF IN SYNTHESIS OF PHARMACEUTICAL CHEMICALSApril 2021June 2023Allow2631YesNo
17237618REPURPOSING INFLATABLE PACKAGING PILLOWS AS BIOREACTORS: CONVENIENT SYNTHESIS OF GLUCOSONE BY WHOLE-CELL CATALYSIS UNDER OXYGENApril 2021July 2024Allow3821YesNo
17229543SEMISYNTHETIC ROUTES TO ORGANIC COMPOUNDSApril 2021August 2024Allow4021YesNo
17284837PROTEIN-POLYMER CONJUGATES AND METHODS FOR THEIR PREPARATIONApril 2021April 2025Abandon4841YesNo
17284186METHOD FOR RECYCLABLY USING AN ENZYMEApril 2021August 2022Allow1601NoNo
17224008TRANSAMINASE POLYPEPTIDESApril 2021August 2022Allow1711YesNo
17221308Method for Producing Target Substance by Bacterial FermentationApril 2021January 2024Allow3420YesNo
17221613BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDSApril 2021August 2022Allow1711YesNo
17217912NUCLEIC ACID MOLECULES ENCODING NUCLEASE-ALBUMIN FUSION PROTEINSMarch 2021July 2024Allow4021YesNo
17205008CONTROLLABLE PROTEIN DEGRADATION VIA ENGINEERING DEGRADATION TAG VARIANTS IN CORYNEBACTERIUM HOST CELLSMarch 2021May 2024Abandon3821NoNo
17204244VARIANTS AND COMPOSITIONS COMPRISING VARIANTS WITH HIGH STABILITY IN PRESENCE OF A CHELATING AGENTMarch 2021June 2022Allow1520YesNo
17273140ENRICHING DHA IN GLYCERIDE FRACTIONSMarch 2021July 2023Allow2920YesNo
17267590SYSTEM AND METHOD FOR TREATING BIOMASS MATERIALFebruary 2021December 2023Allow3411YesNo
17265277Protein C-Factor VII ChimerasFebruary 2021July 2022Allow1721YesNo
17264758BIOSYNTHETIC PLATFORM FOR THE PRODUCTION OF CANNABINOIDS AND OTHER PRENYLATED COMPOUNDSJanuary 2021June 2022Allow1611YesNo
17264748Non-Specific Nucleases from the Genus Pseudomonas for Use in Facilitating Flow of Cells Through a Microfluidic ChannelJanuary 2021January 2024Allow3641YesNo
17157880PROGRAMMABLE PROTEIN CIRCUITS IN LIVING CELLSJanuary 2021December 2023Allow3511YesNo
17150900MICROORGANISM FOR FERMENTATIVE PRODUCTION OF 2-PHENYLETHANOL FROM GASEOUS SUBSTRATESJanuary 2021October 2024Allow4531YesNo
17148834ENGINEERED TYROSINE AMMONIA LYASEJanuary 2021April 2022Allow1521YesNo
17259616IN VIVO POST-TRANSLATIONAL PROCESSING OF TARGET PROTEIN BY FURIN IN PLANTS: ENGINEERING, EXPRESSION AND PRODUCTION OF FUNCTIONAL ACTIVE HUMAN FURIN IN N. BENTHAMIANA PLANTSJanuary 2021July 2023Abandon3011NoNo
17135163ENZYMES OF LUCIFERIN BIOSYNTHESIS AND USE THEREOFDecember 2020December 2023Abandon3511YesNo
17132117Methods and Compositions for Oral Administration of ProteinsDecember 2020January 2023Allow2511YesNo
17127570METHOD OF PURIFYING CANNABINOIDS FROM YEAST FERMENTATION BROTHDecember 2020March 2022Abandon1510NoNo
17252454HUMAN CGAS-DNA COMPLEX AND ENCODED PROTEINDecember 2020July 2024Allow4341YesNo
17120160CONSTRUCTION OF MUCOR CIRCINELLOIDES CELL FACTORY FOR PRODUCING STEARIDONIC ACID AND FERMENTATION TECHNOLOGY THEREOFDecember 2020April 2022Allow1621YesNo
17108020POLYPEPTIDES HAVING LIPASE ACTIVITY AND POLYNUCLEOTIDES ENCODING SAMEDecember 2020May 2022Allow1821YesNo
17059999OVER-EXPRESSION OF TRANSCRIPTIONAL ACTIVATOR/REPRESSOR GIS1 IN YEAST FOR INCREASED ETHANOL PRODUCTIONNovember 2020October 2022Abandon2211NoNo
17059979PROCESS FOR PRODUCING PHYCOCYANIN-RICH BIOMASS VIA URA CULTURINGNovember 2020September 2022Allow2220YesNo
17102361MANGANESE SUPPLEMENTATION FOR CONTROL OF GLYCOSYLATION IN MAMMALIAN CELL CULTURE PROCESSNovember 2020February 2023Abandon2711NoNo
17054526MANNANASE PMAN5A MUTANT HAVING IMPROVED HEAT RESISTANCE, GENE THEREOF, AND APPLICATIONNovember 2020April 2022Allow1711YesNo
17085135OILS, LIPIDS AND FATTY ACIDS PRODUCED IN TRANSGENIC BRASSICA PLANTOctober 2020February 2022Abandon1620NoNo
17051514TRANSFORMANT OF CORYNEFORM BACTERIUM AND PRODUCTION METHOD FOR USEFUL COMPOUND USING SAMEOctober 2020March 2022Allow1720YesNo
17050549PROCESS AND SYSTEM FOR MICROBIAL FERMENTATIONOctober 2020September 2024Abandon4711NoNo
17078613ANTIMICROBIAL PEPTIDE ID13, PREPARATION METHOD AND USE THEREOFOctober 2020August 2023Allow3421YesNo
17046993Method for Manufacturing Bacterium-Produced Cellulose CarbonOctober 2020July 2022Allow2120YesNo
17068262MICROORGANISMS WITH ENHANCED CARBON MONOXIDE AVAILABILITY AND USE THEREOFOctober 2020September 2022Allow2311YesNo
17045149PAENIBACILLUS PABULI-DERIVED ENZYME CAPABLE OF PRODUCING GALACTO-OLIGOSACCHARIDE, AND METHOD FOR PRODUCING GALACTO-OLIGOSACCHARIDEOctober 2020February 2024Allow4741YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ROBINSON, HOPE A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
16
Examiner Affirmed
10
(62.5%)
Examiner Reversed
6
(37.5%)
Reversal Percentile
57.5%
Higher than average

What This Means

With a 37.5% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
104
Allowed After Appeal Filing
29
(27.9%)
Not Allowed After Appeal Filing
75
(72.1%)
Filing Benefit Percentile
38.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 27.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ROBINSON, HOPE A - Prosecution Strategy Guide

Executive Summary

Examiner ROBINSON, HOPE A works in Art Unit 1652 and has examined 1,199 patent applications in our dataset. With an allowance rate of 62.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner ROBINSON, HOPE A's allowance rate of 62.8% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ROBINSON, HOPE A receive 2.22 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ROBINSON, HOPE A is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +50.7% benefit to allowance rate for applications examined by ROBINSON, HOPE A. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 22.7% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 46.8% of cases where such amendments are filed. This entry rate is in the 65% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 83.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 63% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 78.1% of appeals filed. This is in the 66% percentile among all examiners. Of these withdrawals, 78.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 72.8% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 10.3% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 36.9% of allowed cases (in the 96% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.